Table 2 Characteristics of patients enrolled in CVOTs referred to in the text
From: Current perspectives on cardiovascular outcome trials in diabetes
| Â | Age | Diabetes type | HbA1c levels | Cardiovascular status | Prior antihyperglycemic treatment | BMI (kg/m2) |
|---|---|---|---|---|---|---|
SAVOR-TIMI53 | ≥40 | T2DM | ≥6.5 % | CVD OR high CV risk | AHA | 31.1 |
EXAMINE | ≥18 | T2DM | (6.5, 11.0 %) | ACS (15, 90) days before | AHA | 28.7 |
TECOS | ≥50 | T2DM | (6.5, 11.0 %) | preexisting CVD | AHA | 30.2 |
ELIXA | ≥30 | T2DM | ≥7.0 % | ACS min. 180 days before | AHA | 30.2 |
EMPA-REG OUTCOME | ≥18 | T2DM | (7.0, 10.0 %) | Preexisting CVD | Drug näive OR AHA | ≤45 |
LEADER | ≥50 | T2DM | ≥7.0 % | Preexisting CVD/cerebrovascular disease/vascular disease/renalORheart failure at ≥50 OR CV risk at ≥60 | Drug näive OR AHA | 32.5 |
SUSTAIN-6 | ≥50 | T2DM | ≥7.0 % | Preexisting CVD at ≥50 OR preCVD at ≥60 | Drug näive OR AHA | 31.1 |
EXSCEL | ≥18 | T2DM | (7.0, 10.0 %) |  | Specific AHA |  |
CAROLINA | ≥40 ≤85 | T2DM | (6.5, 7.5–8.5 %) | CVD OR specified diabetes end-organ damage OR age ≥70 years OR ≥2 specified CV risk factors |  | ≤45 |
REWIND | ≥50 | T2DM | ≤9.5 % | Preexisting vascular disease OR ≥CV risk factors | AHA |  |
ITCA650 | ≥40 | T2DM | ≥6.5 % | Preexisting coronary, cerebrovascular or peripheral artery disease |  |  |
DECLARE-TIMI | ≥40 | T2DM |  | High risk CV events |  |  |
CARMELINA | ≥18 | T2DM | (6.5, 10.0 %) | High risk CV events | Drug näive OR specific AHA | ≤45 |
DEVOTE | ≥50 | T2DM | ≤7.0 % | CVD OR renal disease OR ≥60 CV risk | Specific AHA |  |
MK-3102 | ≥40 | T2DM | (6.5, 10.0 %) | Preexisting vascular disease |  |  |
Ertugliflozin trial | ≥40 | T2DM | (7.0, 10.5 %) | Preexisting vascular disease | Drug näive OR AHA | ≥18 |
TOSCA-IT | ≥50 ≤75 | T2DM | (7.0, 9.0 %) |  | Specific AHA | 20–45 |
CANVAS | ≥40 | T2DM | (7.0, 10.5 %) | Preexisting CVD OR high CV risk | Drug näive OR AHA |  |